Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection | Zendy

Bruce R. Bacon | Zendy; Stuart C. Gordon | Zendy; Eric Lawitz | Zendy; Patrick Marcellin | Zendy; John M. Vierling | Zendy; Stefan Zeuzem | Zendy; Fred Poordad | Zendy; Zachary Goodman | Zendy; Heather L. Sings | Zendy; Navdeep Boparai | Zendy; Margaret Burroughs | Zendy; Clifford A. Brass | Zendy; Janice K. Albrecht | Zendy; Rafael Esteban | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

Author(s) -

Bruce R. Bacon,

Stuart C. Gordon,

Eric Lawitz,

Patrick Marcellin,

John M. Vierling,

Stefan Zeuzem,

Fred Poordad,

Zachary Goodman,

Heather L. Sings,

Navdeep Boparai,

Margaret Burroughs,

Clifford A. Brass,

Janice K. Albrecht,

Rafael Esteban

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1009482

Subject(s) - boceprevir , medicine , ribavirin , virology , hepatitis c virus , genotype , ns3 , telaprevir , chronic hepatitis , protease inhibitor (pharmacology) , virus , protease , immunology , viral load , gene , biology , enzyme , antiretroviral therapy , biochemistry

In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal. Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an additional treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research